Table 1 Characteristics of the patients included in this study.
Total N = 41 n (%) | Control group n = 20 n (%) | Intervention group n = 21 n (%) | p-Value | Effect size | |
|---|---|---|---|---|---|
Demographic data | |||||
Age in years (x (sd)) | 71.8 (12.1) | 72.7 (12.7) | 71.0 (11.5) | 0.639 | 0.148 |
Male gender | 24 (58.5%) | 14 (70.0%) | 10 (47.6%) | 0.212 | 0.227 |
Personal history | |||||
High blood pressure (HBP) | 31 (75.6%) | 12 (60.0%) | 19 (90.5%) | 0.031 | 0.355 |
Mellitus diabetes | 19 (46.3%) | 7 (35.0%) | 12 (57.1%) | 0.209 | 0.222 |
Ischemic heart disease | 9 (22.0%) | 3 (15.0%) | 6 (28.6%) | 0.458 | 0.164 |
Cerebrovascular disease | 3 (7.3%) | 2 (10.0%) | 1 (4.8%) | 0.606 | 0.101 |
Obesity | 5 (12.2%) | 1 (5.0%) | 4 (19.0%) | 0.360 | 0.215 |
Dyslipidaemia | 23 (56.1%) | 11 (55.0%) | 12 (57.1%) | 1.000 | 0.022 |
Chronic obstructive pulmonary disease | 4 (9.8%) | 1 (5.0%) | 3 (14.3%) | 0.606 | 0.156 |
Previous chronic treatment | |||||
Antihypertensives | 12 (29.3%) | 3 (15.0%) | 9 (42.9%) | 0.085 | 0.306 |
Insulin | 4 (9.8%) | 3 (15.0%) | 1 (4.8%) | 0.343 | 0.172 |
Oral antidiabetic drugs | 4 (9.8%) | 1 (4.8%) | 3 (15.0%) | 0.606 | 0.156 |
Platelet aggregation inhibitors | 10 (24.4%) | 3 (15.0%) | 7 (33.3%) | 0.285 | 0.213 |
Statins | 11 (26.8%) | 6 (30.0%) | 5 (23.8%) | 0.736 | 0.070 |
Diuretics | 8 (19.5%) | 3 (15.0%) | 5 (23.8%) | 0.691 | 0.111 |
Omeprazole | 10 (24.4%) | 2 (10.0%) | 8 (38.1%) | 0.068 | 0.327 |
Signs and symptoms initial assessment | |||||
Chest pain | 11 (26.8%) | 4 (20.0%) | 7 (33.3%) | 0.499 | 0.150 |
Nausea | 2 (4.9%) | 2 (10.0%) | 0 (0.0%) | 0.236 | 0.232 |
Sweating | 5 (12.2%) | 3 (15.0%) | 2 (9.5%) | 0.663 | 0.084 |
Dysarthria | 2 (4.9%) | 1(5.0%) | 1 (4.8%) | 1.000 | 0.006 |
Clinical characteristics at the beginning of the transfer (mean (SD)) | |||||
SBP (mmHg) | 120.5 (29.5) | 126.9 (25.0) | 114.0 (31.0) | 0.151 | 0.457 |
DBP (mmHg) | 72.3 (16.1) | 74.3 (13.4) | 70.3 (17.8) | 0.419 | 0.255 |
HR (lpm) | 84.5 (19.9) | 87.8 (24.0) | 81.2 (14.4) | 0.289 | 0.336 |
Shock index (HR/SBP) | 0.8 (0.5) | 0.7 (0.3) | 0.9 (0.7) | 0.336 | 0.304 |
RR (rpm) | 21.4 (7.5) | 21.3 (7.2) | 21.5 (7.5) | 0.928 | 0.028 |
SpO2 (%) | 94.4 (3.9) | 94.0 (4.7) | 94.7 (2.8) | 0.603 | 0.164 |
EtCO2 (mmHg) | 28.8 (5.2) | 27.9 (4.1) | 29.8 (5.9) | 0.244 | 0.370 |
VAS (0–10) | 1.6 (2.3) | 1.3 (1.9) | 1.9 (2.5) | 0.435 | 0.247 |
BIS (0–100) | 94.0 (8.2) | 94.4 (6.1) | 93.8 (9.2) | 0.797 | 0.081 |
Drugs administered during transfer | |||||
Nitrates/Antiarrhythmics | 11(26.8%) | 9 (45.0%) | 2 (9.5%) | 0.017 | 0.400 |
Opioids | 7 (17.1%) | 5 (25.0%) | 2 (9.5%) | 0.244 | 0.206 |
Antiemetics | 5 (12.2%) | 4 (20.0%) | 1 (4.8%) | 0.189 | 0.233 |
Benzodiazepines | 1 (2.4%) | 1 (5.0%) | 0 (0.0%) | 0.471 | 0.162 |
Tenecteplase | 1 (2.4%) | 0 (0.0%) | 1 (4.8%) | 1.000 | 0.154 |
Enoxoparin | 2 (4.9%) | 1 (5.0%) | 1 (4.8%) | 1.000 | 0.006 |
Furosemide | 1 (2.4%) | 0 (0.0%) | 1 (4.8%) | 1.000 | 0.154 |
Ranitidine | 1 (2.4%) | 1 (0.0%) | 0 (0.0%) | 0.471 | 0.162 |
